Cancer Immunotherapy News and Research

RSS

Overcoming cancer relapse with CAR-Enhancer therapy

Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse. In a new study, Dana-Farber Cancer Institute researchers report on a technique with the potential to eliminate that problem.

26 Jul 2024

CD5 knockout using CRISPR boosts CAR T cell therapy efficacy

The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on the surface of T cells, according to a preclinical study from investigators at the University of Pennsylvania's Perelman School of Medicine and Abramson Cancer Center.

19 Jul 2024

Researchers discover key functions of IRF1 in cancer progression and treatment response

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have uncovered new details about the role of a protein called interferon regulatory factor (IRF1) in cancer progression and treatment response, offering new insight that can potentially help improve the effectiveness of cancer immunotherapy.

15 Jul 2024

CD22-targeted CAR-T therapy shows promising results in relapsed large B-cell lymphoma

CAR-T cell therapy, which targets a specific protein on the surface of cancer cells, causes tumors to shrink or disappear in about half of patients with large B-cell lymphoma who haven't experienced improvement with chemotherapy treatments.

11 Jul 2024

Novel Co-STAR cells show promise in targeting and eradicating cancer

Using genetic engineering techniques, investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center, the Lustgarten Laboratory and Bloomberg~Kimmel Institute for Cancer Immunotherapy have designed a novel type of cell to recognize and fight cancer.

11 Jul 2024

Live biotherapeutic product can improve clinical outcomes for patients with kidney cancer

Physician scientists from City of Hope, one of the largest cancer research and treatment organizations in the United States, found that people with metastatic kidney cancer who orally took a live biotherapeutic product called CBM588 while in treatment with immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes.

28 Jun 2024

FDA expands orphan drug designation for Roswell Park's brain cancer immunotherapy

The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center.

25 Jun 2024

JAK1 inhibition and Anti-PD1 therapy enhance outcomes in advanced lung cancer

Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from a small clinical trial led by investigators at the Abramson Family Cancer Center at the University of Pennsylvania Perelman School of Medicine.

21 Jun 2024

Combination therapy shows great promise as a new strategy against advanced lung cancer

21 Jun 2024

Combining JAK inhibitors with checkpoint inhibitors improves cancer immunotherapy response

Because not all cancer patients respond to a leading type of cancer immunotherapy drug, known as an immune checkpoint inhibitor, scientists explored whether adding janus kinase (JAK) inhibitors – drugs that treat chronic inflammation – could help.

20 Jun 2024

New research sheds light on IL-23's role in chronic inflammatory bowel diseases

Scientists at Weill Cornell Medicine discovered a previously unknown link between two key pathways that regulate the immune system in mammals-;a finding that impacts our understanding of chronic inflammatory bowel diseases (IBD).

12 Jun 2024

Macrophages play an unexpected role in the complicated obesity-cancer connection

Immune system cells called macrophages play an unexpected role in the complicated connection between obesity and cancer, a Vanderbilt University Medical Center-led research team has discovered.

12 Jun 2024

Targeting epigenetic enzymes in dendritic cells to improve cancer immunotherapy

Immunotherapy is one of the pillars in the fight against cancer and aims to enable the body's own immune system to fight a tumor.

7 Jun 2024

Researchers identify a potential metabolic target for cancer immunotherapy

Researchers at the VIB-KU Leuven Center for Cancer Biology have identified a potential target for cancer immunotherapy.

6 Jun 2024

UC San Diego Health launches personalized immunotherapy for metastatic melanoma

UC San Diego Health is the first hospital system in the region to offer a new immunotherapy treatment for metastatic melanoma.

4 Jun 2024

Understanding the role of tumor-associated fibrosis in immunotherapy resistance

Immunotherapy is based on harnessing a person's own immune system to attack cancer cells.

4 Jun 2024

Wistar scientists develop Persistent Multivalent T Cell Engager for advanced kidney cancer

Advanced clear cell renal cell carcinoma (ccRCC) is a deadly form of kidney cancer with few treatment options; even with new immunotherapies, only around one in 10 patients ultimately survive.

4 Jun 2024

Research reveals how Regnase-1 deficiency enhances NK cell tumor killing

Natural killer (NK) cells play a crucial role in the first line of host defense by eliminating bacteria, viruses, and mutated cells that might become cancer cells.

30 May 2024

Novel therapy reprograms immune cells, shrinks prostate and bladder cancers in animal study

A novel therapy that reprograms immune cells to promote antitumor activity helped shrink hard-to-treat prostate and bladder cancers in mice, according to research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy and Johns Hopkins Drug Discovery.

21 May 2024

Gut bacteria Ruminococcus gnavus can enhance the effects of cancer immunotherapy

Roughly one in five cancer patients benefits from immunotherapy – a treatment that harnesses the immune system to fight cancer.

17 May 2024

Cancer Immunotherapy News and Research

Overcoming cancer relapse with CAR-Enhancer therapy

CD5 knockout using CRISPR boosts CAR T cell therapy efficacy

Researchers discover key functions of IRF1 in cancer progression and treatment response

CD22-targeted CAR-T therapy shows promising results in relapsed large B-cell lymphoma

Novel Co-STAR cells show promise in targeting and eradicating cancer

Live biotherapeutic product can improve clinical outcomes for patients with kidney cancer

FDA expands orphan drug designation for Roswell Park's brain cancer immunotherapy

JAK1 inhibition and Anti-PD1 therapy enhance outcomes in advanced lung cancer

Combination therapy shows great promise as a new strategy against advanced lung cancer

Combining JAK inhibitors with checkpoint inhibitors improves cancer immunotherapy response

New research sheds light on IL-23's role in chronic inflammatory bowel diseases

Macrophages play an unexpected role in the complicated obesity-cancer connection

Targeting epigenetic enzymes in dendritic cells to improve cancer immunotherapy

Researchers identify a potential metabolic target for cancer immunotherapy

UC San Diego Health launches personalized immunotherapy for metastatic melanoma

Understanding the role of tumor-associated fibrosis in immunotherapy resistance

Wistar scientists develop Persistent Multivalent T Cell Engager for advanced kidney cancer

Research reveals how Regnase-1 deficiency enhances NK cell tumor killing

Novel therapy reprograms immune cells, shrinks prostate and bladder cancers in animal study

Gut bacteria Ruminococcus gnavus can enhance the effects of cancer immunotherapy

E-Cigarettes and Ethanol: A forensic Perspective on Vaping

Understanding Consumer-Consented Data to Optimize Digital Health Programs

The Future is Wearable: Advancing Human Health Through Portable Spectroscopy

Latest News